Literature DB >> 17526823

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.

.   

Abstract

Computer simulation models are mathematical equations combined in a structured framework to represent some real or hypothetical system. One of their uses is to allow the projection of short-term data from clinical trials to evaluate clinical outcomes and costs over a long-term period. This technology is becoming increasingly important to assist decision making in modern medicine in situations where there is a paucity of long-term clinical trial data, as recently acknowledged in the American Diabetes Association Consensus Panel Guidelines for Computer Modeling of Diabetes and its Complications. The Mount Hood Challenge Meetings provide a forum for computer modelers of diabetes to discuss and compare models and identify key areas of future development to advance the field. The Fourth Mount Hood Challenge in 2004 was the first meeting of its kind to ask modelers to perform simulations of outcomes for patients in published clinical trials, allowing comparison against "real life" data. Eight modeling groups participated in the challenge. Each group was given three of the following challenges: to simulate a trial of type 2 diabetes (CARDS [Collaborative Atorvastatin Diabetes Study]); to simulate a trial of type 1 diabetes (DCCT [Diabetes Control and Complications Trial]); and to calculate outcomes for a hypothetical, precisely specified patient (cross-model validation). The results of the models varied from each other and for methodological reasons, in some cases, from the published trial data in important ways. This approach of performing systematic comparisons and validation exercises has enabled the identification of key differences among the models, as well as their possible causes and directions for improvement in the future.

Entities:  

Mesh:

Year:  2007        PMID: 17526823     DOI: 10.2337/dc07-9919

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  75 in total

1.  Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009.

Authors:  Benjamin M Craig; Marc Brisson; Harrell Chesson; Anna R Giuliano; Mark Jit
Journal:  Clin Ther       Date:  2010-08       Impact factor: 3.393

Review 2.  Simulation models of obesity: a review of the literature and implications for research and policy.

Authors:  D T Levy; P L Mabry; Y C Wang; S Gortmaker; T T-K Huang; T Marsh; M Moodie; B Swinburn
Journal:  Obes Rev       Date:  2010-10-26       Impact factor: 9.213

3.  Let cost effectiveness models be open to scrutiny.

Authors:  Chris Poole; Samir Agrawal; Craig J Currie
Journal:  BMJ       Date:  2007-10-13

4.  Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

Authors:  Charalampos Tzanetakos; Alexandra Bargiota; Georgia Kourlaba; George Gourzoulidis; Nikos Maniadakis
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

5.  Requisite models for strategic commissioning: the example of type 1 diabetes.

Authors:  Mara Airoldi; Gwyn Bevan; Alec Morton; Mónica Oliveira; Jenifer Smith
Journal:  Health Care Manag Sci       Date:  2008-06

6.  Simulating lifetime outcomes associated with complications for people with type 1 diabetes.

Authors:  Tom W C Lung; Philip M Clarke; Alison J Hayes; Richard J Stevens; Andrew Farmer
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

Review 7.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Simple calculator to estimate the medical cost of diabetes in sub-Saharan Africa.

Authors:  Koffi Alouki; Hélène Delisle; Stéphane Besançon; Naby Baldé; Assa Sidibé-Traoré; Joseph Drabo; François Djrolo; Jean-Claude Mbanya; Serge Halimi
Journal:  World J Diabetes       Date:  2015-11-25

Review 9.  Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.

Authors:  Sanjib Saha; Ulf-G Gerdtham; Pia Johansson
Journal:  Int J Environ Res Public Health       Date:  2010-08-09       Impact factor: 3.390

10.  Projecting the future diabetes population size and related costs for the U.S.

Authors:  Elbert S Huang; Anirban Basu; Michael O'Grady; James C Capretta
Journal:  Diabetes Care       Date:  2009-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.